📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies. (2023)

First Author: Mesa RA

Attributed to: Unravelling biological heterogeneity in neoplastic myeloproliferative stem cells funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/cam4.5799

PubMed Identifier: 37021939

Publication URI: http://europepmc.org/abstract/MED/37021939

Type: Journal Article/Review

Volume: 12

Parent Publication: Cancer medicine

Issue: 9

ISSN: 2045-7634